MAPT and Alzheimer disease: Patients were then divided, based on their CSF biomarkers’ values, into amyloid-positive and amyloid-negative, t-Tau-positive and t-Tau-negative, p-Tau-positive and p-Tau-negative (according to our laboratory cut-off values) and patients with AD and non-AD profiles (Figure 1).